NextCure, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Fundamentals are temporarily unavailable for NXTC.
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Research & Development | $54.20M | $47.93M | $41.49M | $44.92M |
| Selling, General & Admin | $21.71M | $19.71M | $15.72M | $12.69M |
| Operating Expenses | $75.91M | $67.64M | $57.21M | $57.62M |
| Operating Income | -$75.91M | -$67.64M | -$57.21M | -$57.62M |
| EBITDA | -$71.78M | -$63.95M | -$54.34M | -$55.43M |
| Pretax Income | -$74.73M | -$62.72M | -$55.65M | -$55.84M |
| Net Income | -$74.73M | -$62.72M | -$55.65M | -$55.84M |
| Diluted EPS | -32.28 | -27.00 | -23.88 | -19.65 |
| Diluted Shares | 2.31M | 2.32M | 2.33M | 2.84M |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & Equivalents | $26.63M | $13.08M | $27.73M | $25.98M |
| Current Assets | $163.98M | $112.72M | $71.81M | $43.75M |
| Total Assets | $184.16M | $128.04M | $80.86M | $50.18M |
| Current Liabilities | $9.13M | $6.88M | $9.57M | $10.57M |
| Total Debt | $7.12M | $6.61M | $5.95M | $5.15M |
| Total Liabilities | $16.63M | $13.62M | $15.39M | $15.24M |
| Retained Earnings | -$261.76M | -$324.48M | -$380.14M | -$435.98M |
| Shareholders' Equity | $167.53M | $114.42M | $65.47M | $34.94M |
| Working Capital | $154.86M | $105.84M | $62.23M | $33.18M |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | -$53.89M | -$52.97M | -$40.80M | -$49.61M |
| Capital Expenditure | -$2.12M | -$820.00K | -$474.00K | — |
| Free Cash Flow | -$56.00M | -$53.79M | -$41.28M | -$49.61M |
| Depreciation & Amortisation | $4.12M | $3.68M | $2.87M | $2.19M |
| Stock-Based Compensation | $9.51M | $8.19M | $6.33M | $2.99M |
| Investing Cash Flow | $67.98M | $39.27M | $55.31M | $25.56M |
| Financing Cash Flow | $200.00K | $154.00K | $144.00K | $22.31M |
| Net Change in Cash | $14.29M | -$13.55M | $14.64M | -$1.75M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research & Development | $7.90M | $24.09M | $6.14M | $6.80M | $6.83M | $7.42M |
| Selling, General & Admin | $3.73M | $3.20M | $2.81M | $2.96M | $3.27M | $2.59M |
| Operating Expenses | $11.62M | $27.29M | $8.95M | $9.76M | $10.11M | $10.02M |
| Operating Income | -$11.62M | -$27.29M | -$8.95M | -$9.76M | -$10.11M | -$10.02M |
| EBITDA | -$10.97M | -$26.66M | -$8.41M | -$9.39M | -$9.82M | -$9.74M |
| Pretax Income | -$10.98M | -$26.81M | -$8.62M | -$9.44M | -$9.80M | -$14.89M |
| Net Income | -$10.98M | -$26.81M | -$8.62M | -$9.44M | -$9.80M | -$14.89M |
| Diluted EPS | -4.70 | -11.29 | -3.22 | — | -1.87 | -2.80 |
| Diluted Shares | 2.33M | 2.37M | 2.68M | — | 5.24M | 5.31M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.83M | $4.89M | $7.32M | $25.98M | $15.17M | $15.26M |
| Current Assets | $58.90M | $40.02M | $32.64M | $43.75M | $31.74M | $22.25M |
| Total Assets | $67.14M | $47.69M | $39.61M | $50.18M | $37.98M | $22.62M |
| Current Liabilities | $5.74M | $10.78M | $10.99M | $10.57M | $6.89M | $6.41M |
| Total Debt | $4.91M | $4.67M | $4.41M | $5.15M | $3.88M | $3.60M |
| Total Liabilities | $11.28M | $16.04M | $15.97M | $15.24M | $11.26M | $10.47M |
| Retained Earnings | -$391.11M | -$417.92M | -$426.54M | -$435.98M | -$445.78M | -$460.67M |
| Shareholders' Equity | $55.85M | $31.65M | $23.65M | $34.94M | $26.72M | $12.15M |
| Working Capital | $53.16M | $29.23M | $21.64M | $33.18M | $24.85M | $15.84M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.99M | -$22.71M | -$6.27M | -$7.64M | -$13.36M | -$9.71M |
| Free Cash Flow | -$12.99M | -$22.71M | -$6.27M | -$7.64M | -$13.36M | -$9.71M |
| Depreciation & Amortisation | $654.00K | $633.00K | $533.00K | $365.00K | $283.00K | $272.00K |
| Stock-Based Compensation | $1.36M | $588.00K | $600.00K | $435.00K | $344.00K | $304.00K |
| Investing Cash Flow | $7.09M | $3.76M | $8.70M | $6.00M | $1.30M | $9.79M |
| Financing Cash Flow | $0.00 | $2.02M | $0.00 | $20.29M | $1.25M | $22.00K |
| Net Change in Cash | -$5.90M | -$16.93M | $2.43M | $18.66M | -$10.81M | $93.00K |
Market Snapshot
About
NextCure is an immuno-oncology biotechnology company developing novel immunomedicines to treat cancer and other immune-related diseases. The company focuses on modulating the immune system to improve patient outcomes.